Last updated: about 1 month ago
AstraZeneca's Enhertu: Game-Changer for HER2-Low Metastatic Breast Cancer
Explore AstraZeneca's Enhertu approval in the EU for HER2-low breast cancer, backed by significant trial success and a commitment to revolutionizing treatment options.